Failure to remit at endpoint · patients with depression
Paroxetine probably leads to higher failure to remit at endpoint compared with mirtazapine (moderate certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with mirtazapine (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with mirtazapine (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with nefazodone (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
Paroxetine showed no clear difference in failure to respond at 16‐24 weeks compared with nefazodone (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · patients with depression
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with nefazodone (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with nefazodone (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with reboxetine (moderate certainty).
1 finding from 1 review
Treatment responseCGI‐I · people with anxiety and comorbid alcohol use disorders
It is very uncertain whether paroxetine changes treatment responseCGI‐I compared with placebo (very low certainty).
1 finding from 1 review
Symptom severity reductionLSAS · people with anxiety and comorbid alcohol use disorders
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with anxiety and comorbid alcohol use disorders
It is very uncertain whether paroxetine changes treatment acceptability compared with placebo (very low certainty).
1 finding from 1 review
Frequency of use % of heavy drinking days at the end of treatment · people with anxiety and comorbid alcohol use disorders
1 finding from 1 review
Percent of days abstinent · people with anxiety and comorbid alcohol use disorders
1 finding from 1 review
Drinks per drinking day · people with anxiety and comorbid alcohol use disorders
1 finding from 1 review
Depression symptom reduction · people with anxiety and comorbid alcohol use disorders
1 finding from 1 review